A securities class action has been filed against Aardvark Therapeutics, Inc. (NASDAQ: AARD) over alleged misleading disclosures concerning ARD-101's safety and clinical, regulatory and commercial prospects. The case covers investors who purchased or acquired Aardvark common stock under the registration statement and prospectus for the company's February 13, 2025, initial public offering, as well as securities purchased between February 13, 2025, and May 14, 2026, inclusive. Investors seeking appointment as lead plaintiff must ask the court to act by October 13, 2026. Rosen Law Firm said investors may participate without serving as lead plaintiff and that no class has yet been certified.